PED Shield与PED/PED Flex治疗未破裂颅内动脉瘤的多中心倾向匹配比较
经倾向评分匹配后比较PED Shield与PED/PED Flex的围手术期并发症、临床预后及血管造影结果。两组在完全闭塞率、显著支架内狭窄及症状性狭窄方面无显著差异,但PED Shield支架内狭窄(≥25%)发生率更低。
要点
- PED Shield在6-7个月随访时支架内狭窄(≥25%)发生率低于PED/PED Flex(5.0% vs 14.9%,p=0.010)。
- 两组完全闭塞率、显著支架内狭窄(>50%)及症状性狭窄、围手术期并发症和良好预后均无显著差异。
核心结论
- 在6-7个月平均随访时,PED Shield的支架内狭窄(ISS≥25%)发生率低于PED/PED Flex。
- PED Shield与PED/PED Flex在围手术期并发症、临床预后、完全闭塞、显著支架内狭窄及症状性狭窄方面均无显著差异。
研究设计与样本
- 本研究为回顾性分析,数据来自前瞻性维护的数据库,涵盖三家高级卒中中心,时间范围为2016年2月至2024年10月。
- 共纳入1039例PED/PED Flex治疗患者和172例PED Shield治疗患者,采用倾向评分匹配调整性别、年龄、高血压、糖尿病、高脂血症、吸烟、动脉瘤位置、形态、大小、弹簧圈栓塞及随访时长。
- 临床结局匹配164对,血管造影结局匹配121对,注册号NCT06446778。
关键影像表现/征象
- PED Shield组支架内狭窄(ISS≥25%)发生率为5.0%,低于PED/PED Flex组的14.9%(p=0.010)。
诊断标准与关键数值
- 临床预后良好定义为mRS评分0-2,PED Shield组为97.5%,PED/PED Flex组为98.0%,p=0.760。
- 完全闭塞率:PED Shield组80.2%,PED/PED Flex组73.6%,p=0.223。
- 显著支架内狭窄(ISS率>50%):PED Shield组3.3%,PED/PED Flex组5.0%,p=0.749。
- 症状性支架内狭窄:PED Shield组0.0%,PED/PED Flex组2.5%,p=0.247。
- 总围手术期并发症:PED Shield组4.9%,PED/PED Flex组7.9%,p=0.259。
临床应用与阅片要点
- 报告支架内狭窄时应明确阈值定义:≥25%和>50%代表不同临床意义,日常随访中需准确测量并描述狭窄程度。
- 6-7个月短期随访时PED Shield的轻度支架内狭窄(≥25%)更少,但完全闭塞率和显著狭窄两装置相当。
- 随访报告应同时关注临床状态(mRS评分)与血管造影结果,不能仅依据狭窄程度判断装置优劣。
局限性
- 本研究为回顾性分析,存在选择性偏倚可能。
- 血管造影随访仅匹配121对,少于临床随访的164对。
- 平均随访时间仅6-7个月,症状性狭窄和长期疗效仍需更长时间观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Pipeline Flex Embolization Device with Shield Technology (PED Shield) is designed to reduce the incidence of thrombosis events through phosphorylcholine coating. However, the comparative efficacy and safety of PED Shield and PED/PED Flex remain unclear.
METHODS: We conducted a retrospective analysis of a prospectively maintained database at three advanced stroke centers from February 2016 to October 2024. Propensity score matching was employed to adjust for sex, age, hypertension, diabetes, hyperlipidemia, smoking, aneurysm location, morphology, size, coiling and follow-up duration. After matching, perioperative complications and clinical and angiographic outcomes were compared.
RESULTS: 1039 patients treated by PED/PED Flex and 172 patients treated by PED Shield were enrolled. For clinical outcomes, 164 pairs were matched. No significant differences were found in total perioperative complications (7.9% vs. 4.9%, p = 0.259) and favourable prognosis (mRS score 0-2, 98.0% vs. 97.5%, p = 0.760) between the PED Shield and PED/PED Flex group. For angiographic outcomes, 121 pairs were matched. No significant differences were observed in complete occlusion (80.2% vs. 73.6%, p = 0.223), significant in-stent stenosis (ISS, ISS rate > 50%) (3.3% vs. 5.0%, p = 0.749) and symptomatic ISS (0.0% vs. 2.5%, p = 0.247) between the PED Shield and PED/PED Flex group. However, PED Shield had a lower incidence of ISS (ISS rate ≥ 25%, 5.0 vs. 14.9%, p = 0.010) at a mean follow-up time of 6-7 months.
CONCLUSION: Compared with PED/PED Flex, PED Shield has a lower rate of ISS at a mean follow-up time of 6-7 months. No significant differences are observed in perioperative complications, clinical outcomes, complete occlusion, significant ISS and symptomatic ISS.
REGISTRATION: URL: https://www.
CLINICALTRIALS: gov ; Unique identifier: NCT06446778.
引用
- Ge, Peng, Chen, et al. Pipeline Shield versus Pipeline Flex for unruptured intracranial aneurysms: a propensity-matched multicenter study. Neuroradiology. 2026. PMID: 42760406. doi:10.1007/s00234-026-04186-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。